These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12677203)

  • 1. PARP as a Drug Target for the Therapy of Diabetic Cardiovascular Dysfunction.
    Szabo C
    Drug News Perspect; 2002 May; 15(4):197-205. PubMed ID: 12677203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation.
    Soriano FG; Virág L; Szabó C
    J Mol Med (Berl); 2001 Aug; 79(8):437-48. PubMed ID: 11511974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
    Virág L; Szabó C
    Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase inhibitors.
    Southan GJ; Szabó C
    Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
    Virág L
    Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
    Komjáti K; Besson VC; Szabó C
    Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death.
    Virág L; Szabó C
    FASEB J; 2001 Jan; 15(1):99-107. PubMed ID: 11149897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribose) polymerase 1 inhibition protects cardiomyocytes from inflammation and apoptosis in diabetic cardiomyopathy.
    Qin WD; Liu GL; Wang J; Wang H; Zhang JN; Zhang F; Ma Y; Ji XY; Li C; Zhang MX
    Oncotarget; 2016 Jun; 7(24):35618-35631. PubMed ID: 27027354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation.
    Garcia Soriano F ; Virág L; Jagtap P; Szabó E; Mabley JG; Liaudet L; Marton A; Hoyt DG; Murthy KG; Salzman AL; Southan GJ; Szabó C
    Nat Med; 2001 Jan; 7(1):108-13. PubMed ID: 11135624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications.
    Szabó C
    Pharmacol Res; 2005 Jul; 52(1):60-71. PubMed ID: 15911334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro.
    Radovits T; Lin LN; Zotkina J; Gero D; Szabó C; Karck M; Szabó G
    Eur J Pharmacol; 2007 Jun; 564(1-3):158-66. PubMed ID: 17397824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity.
    Kiss L; Szabó C
    Mem Inst Oswaldo Cruz; 2005 Mar; 100 Suppl 1():29-37. PubMed ID: 15962096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose)polymerase 1 inhibition protects against age-dependent endothelial dysfunction.
    Zhang GH; Chao M; Hui LH; Xu DL; Cai WL; Zheng J; Gao M; Zhang MX; Wang J; Lu QH
    Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1266-74. PubMed ID: 26331430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation.
    Aguilar-Quesada R; Muñoz-Gámez JA; Martín-Oliva D; Peralta-Leal A; Quiles-Pérez R; Rodríguez-Vargas JM; Ruiz de Almodóvar M; Conde C; Ruiz-Extremera A; Oliver FJ
    Curr Med Chem; 2007; 14(11):1179-87. PubMed ID: 17504138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme.
    Pacher P; Szabó C
    Antioxid Redox Signal; 2005; 7(11-12):1568-80. PubMed ID: 16356120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiological Role of Peroxynitrite Induced DNA Damage in Human Diseases: A Special Focus on Poly(ADP-ribose) Polymerase (PARP).
    Islam BU; Habib S; Ahmad P; Allarakha S; Moinuddin ; Ali A
    Indian J Clin Biochem; 2015 Oct; 30(4):368-85. PubMed ID: 26788021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes.
    Pacher P; Liaudet L; Soriano FG; Mabley JG; Szabó E; Szabó C
    Diabetes; 2002 Feb; 51(2):514-21. PubMed ID: 11812763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.